Black Bird Biotech Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Black Bird Biotech has been growing earnings at an average annual rate of 63.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 61% per year.
Anahtar bilgiler
63.7%
Kazanç büyüme oranı
85.8%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | -61.0% |
| Özkaynak getirisi | n/a |
| Net Marj | -2,301.9% |
| Son Kazanç Güncellemesi | 30 Sep 2023 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Gelir ve Gider Dağılımı
Black Bird Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -1 | 0 | 0 |
| 30 Jun 23 | 0 | -1 | 0 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -2 | 2 | 0 |
| 30 Jun 22 | 0 | -3 | 2 | 0 |
| 31 Mar 22 | 0 | -2 | 2 | 0 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Kaliteli Kazançlar: BBBT is currently unprofitable.
Büyüyen Kar Marjı: BBBT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if BBBT's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare BBBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: BBBT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: BBBT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.